Released Mar 22, 2023, after the close
10-K filed Mar 22, 2023, 81 days after period end · 0000950170-23-009184
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$22.40M-$22.40M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$22,978,000N/M
Operating Cash Flowderived-$19,254,000N/M
Free Cash Flowderived-$19,254,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | — | $1.04M | $4.77M |
| Net Income | -$22.40M | -$60.26M | -$39.42M | -$27.08M |
| EPS Diluted | — | — | -$1.11 | -$0.99 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR